The diabetics face difficulty in breaking down the carbohydrates as their body develops resistance against a protein, insulin, and are more likely to have a heart stroke, kidney problems, blindness and other major health complications.

The Food and Drug Administration has approved Tradjenta tablets for adults suffering from the type-2 diabetes and not able to control their blood sugar with older medicines. The type-2 is the most common form of diabetes that affects approximately, 95% of the 24 million people in the U. S. suffering from the diabetes. The medicine obstructs the DPP-4 enzyme, which secretes an insulin boosting hormone and helps to control the blood sugar levels.

Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, said : “Type 2 diabetes is increasing at an alarming rate and we are proud to offer people in the United States a new treatment option from our Boehringer Ingelheim research laboratories that could potentially help the millions of patients with type 2 diabetes whose blood sugar is not adequately controlled”.

The FDA has approved the medicine as a single treatment or sometimes in combination with other recommended medicines for the type 2 diabetes such as metformin, sulphonylurea and pioglitazone.